What drove the intraday drop in 42C.SI stock today?

The drop to **S$0.19** came with unusually high volume of **29,039,300** shares. Traders cited profit-taking after a run-up, overbought technicals (RSI **80.23**), and short-term rebalancing. No single news item was confirmed as the main trigger.

What are realistic near-term price targets for 42C.SI stock?

Near-term resistance sits at **S$0.21** then **S$0.25**. Support is near **S$0.15**. Meyka AI lists monthly and quarterly targets at **S$0.25** and **S$0.34** respectively, with model risk acknowledged.

How does Meyka AI rate 42C.SI stock and what does it mean?

Meyka AI rates 42C.SI with a score of **61.43 / 100 (Grade B, HOLD)**. The grade blends benchmark, sector, financials, and analyst signals. It is informational and not a recommendation.

What is the biggest fundamental risk for 42C.SI stock?

The main risk is binary clinical and licensing outcomes combined with thin near-term profitability. The company shows negative EPS and tight cash per share, increasing sensitivity to trial delays or poor results.

SG Stocks

iX Biopharma (42C.SI) down 12.73% intraday 12 Feb 2026: volume surge

ByDanny Kontos February 12, 2026

The most active name on the SES today, iX Biopharma Ltd. (42C.SI) slid 12.73% intraday to S$0.19 on 12 Feb 2026 as trading volume jumped to 29,039,300 shares. This intraday move pushes a previously strong run higher into a sharp pullback. Our intraday coverage looks at why 42C.SI stock is on traders’ screens, how volume and technicals line up, and what model-based forecasts imply for near-term price targets on the Singapore exchange (SES).